tetano
Editor, Senior Moderator
J Med Virol
. 2020 Aug 22.
doi: 10.1002/jmv.26449. Online ahead of print.
Punicalagin is a neuraminidase inhibitor of influenza viruses
Ping Li[SUP] 1 [/SUP], Ruikun Du[SUP] 1 2 3 [/SUP], Zinuo Chen[SUP] 1 [/SUP], Yanyan Wang[SUP] 1 [/SUP], Peng Zhan[SUP] 4 [/SUP], Xinyong Liu[SUP] 4 [/SUP], Dongwei Kang[SUP] 4 [/SUP], Zhaoyu Chen[SUP] 1 [/SUP], Xiujuan Zhao[SUP] 1 [/SUP], Lin Wang[SUP] 1 [/SUP], Lijun Rong[SUP] 5 [/SUP], Qinghua Cui[SUP] 1 2 3 [/SUP]
Affiliations
Abstract
Influenza A virus (IAV) causes great morbidity and mortality worldwide every year. However, there are only a limited number of drugs clinically available against IAV infection. Further, emergence of drug resistant strains can render those drugs ineffective. Thus there is an unmet medical need to develop new anti-influenza agents. In this study, we show that punicalagin from plants possesses strong anti-influenza activity with a low micromolar IC[SUB]50[/SUB] value in tissue culture. Using a battery of bioassays such as single-cycle replication assay, neuraminidase (NA) inhibition assay, and virus yield reduction assay, we demonstrate that the primary mechanism of action (MOA) of punicalagin is the NA-mediated viral release. Moreover, punicalagin can inhibit replication of different strains of influenza A and B viruses, including oseltamivir-resistant virus (NA/H274Y), indicating that punicalagin is a broad spectrum antiviral against both IAV and IBV. Further, although punicalagin targets NA like oseltamivir, it has a different MOA. These results suggest that punicalagin is an influenza NA inhibitor that may be further developed as a novel antiviral against influenza viruses. This article is protected by copyright. All rights reserved.
Keywords: antivirals; influenza viruses; natural product; neuraminidase; punicalagin.
. 2020 Aug 22.
doi: 10.1002/jmv.26449. Online ahead of print.
Punicalagin is a neuraminidase inhibitor of influenza viruses
Ping Li[SUP] 1 [/SUP], Ruikun Du[SUP] 1 2 3 [/SUP], Zinuo Chen[SUP] 1 [/SUP], Yanyan Wang[SUP] 1 [/SUP], Peng Zhan[SUP] 4 [/SUP], Xinyong Liu[SUP] 4 [/SUP], Dongwei Kang[SUP] 4 [/SUP], Zhaoyu Chen[SUP] 1 [/SUP], Xiujuan Zhao[SUP] 1 [/SUP], Lin Wang[SUP] 1 [/SUP], Lijun Rong[SUP] 5 [/SUP], Qinghua Cui[SUP] 1 2 3 [/SUP]
Affiliations
- PMID: 32827314
- DOI: 10.1002/jmv.26449
Abstract
Influenza A virus (IAV) causes great morbidity and mortality worldwide every year. However, there are only a limited number of drugs clinically available against IAV infection. Further, emergence of drug resistant strains can render those drugs ineffective. Thus there is an unmet medical need to develop new anti-influenza agents. In this study, we show that punicalagin from plants possesses strong anti-influenza activity with a low micromolar IC[SUB]50[/SUB] value in tissue culture. Using a battery of bioassays such as single-cycle replication assay, neuraminidase (NA) inhibition assay, and virus yield reduction assay, we demonstrate that the primary mechanism of action (MOA) of punicalagin is the NA-mediated viral release. Moreover, punicalagin can inhibit replication of different strains of influenza A and B viruses, including oseltamivir-resistant virus (NA/H274Y), indicating that punicalagin is a broad spectrum antiviral against both IAV and IBV. Further, although punicalagin targets NA like oseltamivir, it has a different MOA. These results suggest that punicalagin is an influenza NA inhibitor that may be further developed as a novel antiviral against influenza viruses. This article is protected by copyright. All rights reserved.
Keywords: antivirals; influenza viruses; natural product; neuraminidase; punicalagin.